Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Mylotarg 
Synonyms :
gemtuzumab
Class :
Antineoplastics and Monoclonal Antibody
Brand Name :
Mylotarg 
Synonyms :
gemtuzumab
Class :
Antineoplastics and Monoclonal Antibody
Dosage Forms & Strengths   Â
Injection   Â
4.5 mg per single-dose vial   Â
Newly diagnosed CD33-positive acute myeloid leukemia (AML):
COMBINATION REGIMEN
Induction: 3 mg per m2 IV over 2hrs for Days 1, 4, and 7 given in combination with daunorubicin and cytarabine
the drug gemtuzumab during the second induction cycle gemtuzumab isn't encouraged for patients who require a second induction cycle
Consolidation: 3 mg per m2 IV over 2hrs on Day 1 in combination with daunorubicin and cytarabine
Newly diagnosed CD33-positive acute myeloid leukemia (AML):
SINGLE-AGENT REGIMEN:
Induction: 6 mg per m2 IV over 2hrs on Day 1 and 3 mg/m2 IV on Day 8
Continuation: 2 mg per m2 IV over 2hrs on Day 1 every four weeks
Relapsed or Refractory CD33-positive AML:
SINGLE-AGENT REGIMEN:
3 mg per m2 IV over 2hrs on Days 1, 4, and 7
a single course of gemtuzumab given for treatment in the relapsed or refractory setting
Dosage Forms & Strengths   Â
Injection   Â
4.5-mg per single-dose vial       
Newly Diagnosed De Novo CD33-positive AML:
Combination Regimen:
age: >1year
BSA< 0.6 m2: 0.1 mg per kg IV over 2hrs
BSA>0.6 m2: 0.3 mg per m2 IV over 2hrs
INDUCTION 1:
gemtuzumab is given for Induction 1 once in combination with standard chemotherapy
In the second induction cycle, gemtuzumab isn't encouraged
INTENSIFICATION:
in the first or third intensification cycles, gemtuzumab isn't encouraged
gemtuzumab is given for Intensification 2 once in combination with standard chemotherapy
During Intensification 2, check for risks and potential benefits before giving gemtuzumab
Relapsed or Refractory CD33-positive AML:
SINGLE-AGENT REGIMEN:
age: > 2years
3 mg per m2 given IV over 2hrs on Days 1, 4, and 7
a single course of gemtuzumab for treatment in the relapsed or refractory setting
may diminish the therapeutic effect of vaccines
vaccinia immune globulin intravenous (Rx)
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect of vaccines
measles mumps and rubella vaccine, live
may diminish the therapeutic effect of vaccines
measles, mumps, rubella and varicella vaccine, liveÂ
may decrease the therapeutic effects of vaccine
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased risk of adverse effects  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased risk of adverse effects  
when both drugs are combined, there may be an increased risk of adverse effects  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval 
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
may enhance the thrombogenic effect of immune globulin
may enhance the thrombogenic effect of immune globulin
poliovirus vaccine, live, trivalent
may diminish the therapeutic effect of vaccines
poliovirus vaccine inactivated
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
smallpox (vaccinia) vaccine, live
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
measles, mumps, rubella, and varicella vaccine, live (Rx)
they decrease the efficacy of live vaccines
measles mumps and rubella vaccine, live
they decrease the efficacy of live vaccines
A complex is created when the CD33 antigen and the anti-CD33 antibody component of Mylotarg bind together.Â
The calicheamicin derivative is released within the myeloid cell’s lysosomes after internalization. Â
By binding to DNA in the minor groove, the released calicheamicin derivative creates a p-benzene diradical, which causes site-specific DNA double strand breaks.Â
Adverse drug reactions:  Â
Frequency defined  Â
>10%   Â
Hypophosphatemia  Â
Hypokalemia  Â
Infection  Â
Hyponatremia  Â
Prolonged thrombocytopenia   Â
Hemorrhage  Â
AST increased  Â
Alkaline phosphatase increased  Â
Fever  Â
Infection  Â
Increased AST  Â
Bleeding  Â
Nausea and vomiting  Â
Constipation  Â
Mucositis  Â
Headache  Â
Increased ALT  Â
Rash  Â
Sepsis  Â
Gemtuzumab use has been linked to hepatotoxicity, which includes severe or deadly veno-occlusive disease (VOD).Â
The risk of VOD was increased in clinical studies for persons with moderate to severe hepatic impairment before treatment who received larger gemtuzumab doses as monotherapy.Â
Individuals who experience abnormal liver test results: It is advised to monitor liver tests and clinical signs and symptoms of hepatotoxicity more frequently.Â
When a patient has VOD, stop their treatment and follow conventional medical procedures.Â
Contraindication:Â
HypersensitivityÂ
Caution:Â
HepatotoxicityÂ
For individuals receiving gemtuzumab in addition to cytarabine and daunorubicinÂ
Infusion-related reactionsÂ
QT interval prolongationÂ
HemorrhageÂ
Pregnancy warnings:   Â
Breastfeeding warnings:Â
Pregnancy Categories:     Â
More than 80% of patients with AML have leukemic cells that express the CD33 antigen, which mylotarg.Â
Pluripotent hematopoietic stem cells and nonhematopoietic cells do not express the CD33 antigen.Â
This provides the necessary selectivity for mylotarg to target leukemic cells.Â
Mylotarg targets the hematopoietic cells’ expression of the CD33 antigen.Â
It is administered through intravenous route in the form of lyophilized cake powder for reconstitution.Â
Infusion requires the use of an in-line 0.2-micron polyethersulfone (PES) filter.Â
During infusion, use a light-blocking cover to shield the IV bag from light; the infusion line does not require light protection.Â
Diluted solution should infuse intravenously over 2 hours.Â
Gemtuzumab should not be combined or infused with other medications.Â
Patient information leafletÂ
Generic Name: gemtuzumabÂ
Why do we use gemtuzumab?Â
For patients 60 years of age or older with CD33-positive acute myeloid leukemia in first relapse who are not suitable for alternative cytotoxic treatments.Â
It is recommended for the management of CD33-positive AML patients who have not responded to initial treatment or who have relapsed and are at least 2 years old.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
